跳至主導覽 跳至搜尋 跳過主要內容

Erlotinib-associated near-fatal interstitial pneumonitis in A patient with relapsed lung adenocarcinoma

  • Chun Liang Chou
  • , How Wen Ko
  • , Chih Wei Wang
  • , Chih Teng Yu
  • , Han Pin Kuo
  • , Chien Da Huang*
  • *此作品的通信作者
  • Chang Gung University
  • St. Paul's Hospital Taoyuan

研究成果: 期刊稿件 › 文章 › 同儕審查

9 引文 斯高帕斯(Scopus)

摘要

Erlotinib (Tarceva®) is a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Interstitial lung disease, associated with gefitinib (Iressa®) use, has been reported in approximately 1% of patients worldwide. However, the adverse pulmonary effects of erlotinib remain poorly documented. Reviewed English language publications in MEDLINE and PubMed suggest that this report is to be the first case report in English of a histologically-confirmed case of nearfatal interstitial pneumonitis with acute lung injury, associated with erlotinib, in East Asian patients. Physicians are hereby encouraged to promptly evaluate new or worsening pulmonary symptoms so that they can detect early radiographic signs of pulmonary toxicity in patients on erlotinib. If toxicity is confirmed, erlotinib should be discontinued and the patient treated appropriately. The case presented suggests that the outcome of erlotinib-associated pulmonary toxicity with acute respiratory failure may be favorable with adequate early management.

原文英語
頁(從 - 到)100-105
頁數6
期刊Chang Gung Medical Journal
卷33
發行號1
出版品狀態已出版 - 01 2010

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Erlotinib-associated near-fatal interstitial pneumonitis in A patient with relapsed lung adenocarcinoma」主題。共同形成了獨特的指紋。

引用此